Prevalence and Genotypes of Hepatitis B Virus Infection in Patients Underwent Coronary Angiography and Coronary Artery Bypass Grafting in Mazandaran Heart Center, Sari, Iran

Tahoora Mousavi¹, Shervin Ziabakhsh-Tabary², Ali Ghaemiyan³, Mohammad Reza Haghshenas⁴

Cell Molecular Biology Research Center, Mazandaran University of Medical Sciences, Sari, Iran ¹
Cardiac Surgery Department, Mazandaran University of Medical Sciences, Sari, Iran ²
Department of Cardiology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran ³
Department of Microbiology, Molecular and Cell-Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran⁴

Corresponding author: Mohammad Reza Haghshenas. Molecular and Cell Biology Research Center, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran. E-mail: haghshenas2001@yahoo.com

ABSTRACT

Background: Hepatitis B virus (HBV) infection is a major global health problem in the worldwide that associated with significant morbidity and mortality in cardiac surgery. The available data on HBV distribution and genotyping of HBV are very heterogeneous. Therefore in this study, we tried to indicate the prevalence of HBV infections in cardiac catheterization patients referred to health centers in the north of Iran and identified the HBV genotypes using polymerase chain reaction (PCR).

Methods: In this cross-sectional study, we studied 2650 patients who underwent selective coronary artery angiography and coronary artery bypass grafting in Mazandaran heart center, Sari, Iran from 2011 to 2013. All serum samples were examined to detect HBsAg by ELISA test. HBV-DNA was extracted from HBsAg positive samples using Mini Elute Kit from Qiagen and determined the genotypes of HBV by PCR using the Master Mix kit with Taq-DNA polymerase enzyme and with type of specific primers. All samples were examined in the virology laboratory of Sari Medical School.

Results: The mean age of patients was 59.7±10.9 (range, 20 to 81) year that 1590 (60%) patients were male and 1060 (40%) were female. Seventeen cases (0.08 %) were found with hepatitis B virus infection, and the highest rates of infection were reported among those aged 40–60 years old in this study. We found genotype D the predominant type in this study. Conclusion: This study indicates that the prevalence of HBV endemicity in the north of Iran is low and genotype D is the only genotype in patients infected with HBV.

Key words: Hepatitis B virus, Acute Hepatitis, Genotype of HBV, PCR.

1. INTRODUCTION

The acute and chronic consequence of Hepatitis B virus (HBV) infection is the major public health problem worldwide. It can cause liver diseases including chronic hepatitis, cirrhosis and hepatocellular carcinoma (1, 2). The HBV is highly contagious and relatively easy to transmit by blood-to-blood contact, during birth, unprotected sex, and by sharing needles in the tropics. It is estimated that one third of the world population have been infected by HBV and more than 350 million of people live with chronic infection of these; and nearly one million people die annually from complications of chronic hepatitis B (3-4). Throughout the world, carrier variability rate for hepatitis B infection is estimated to be 0.1% to 20% (5), with regions classified as having low (<2%), intermediate (2-7%) and high (>8%) endemicity. In Iran, it is estimated that almost 35% of population have been exposed to HBV and the endemicity is at intermediate level, with a carrier rated 3% (6). It was reported that HBV infection indicates an intermediate rate in this country and the distribution of carrier rate of HBV infection in varies different provinces of Iran (1.3% to 6.3%) (7). After HBV vaccination program, Iran can be considered as one of the countries with low HBV infection endemicity (8). HBV screening of all patients undergoing invasive cardiac procedures can minimize the risk of transmission from one patient to another and also to the catheterization laboratory personnel. In patients with a positive result, proper precautions can be taken and the entire material used for cardiac catheterization can be discarded (9).

The HBV belongs to hepadnaviridae family and is an enveloped, double-stranded DNA genome of approxi-
Prevalence and Genotypes of Hepatitis B Virus Infection in Patients

mately 3200 bass pairs. So far, ten HBV genotypes (A-J) and multiple subtypes have been identified (10-16) and the genotypes of HBV have distinct geographical distribution of the world (17-19). The study was showed that Turkish patients with chronic hepatitis B infection indicated very little genotypic heterogeneity. Genotype D of HBV represented that almost the whole Turkish patient population were infected with HBV (20, 21). In Pakistan, genotype D was the predominant type found in 128 (64%) population were infected with HBV (20, 21). In Pakistan, HBV represented that almost the whole Turkish patient Turkish patients with chronic hepatitis B infection indi-

Most of the world (17-19). The study was showed that the genotypes of HBV have distinct geographical distribution of the world (17-19). The study was showed that Turkish patients with chronic hepatitis B infection indicated very little genotypic heterogeneity. Genotype D of HBV represented that almost the whole Turkish patient population were infected with HBV (20, 21). In Pakistan, genotype D was the predominant type found in 128 (64%) population were infected with HBV (20, 21). In Pakistan, HBV represented that almost the whole Turkish patient population were infected with HBV (20, 21). The study demonstrated that genotype D (35.67%) is the predominant genotype circulating in Afghan population and followed by genotype C (32.16%), genotype A (19.30%), and genotype B (7.02%) (25). In Iran, Genotype D of HBV made almost the whole patient population infected with HBV in different clinical forms (26-30). In the north of Iran, genotype D was found in 93% of HBV positive patients followed by genotype B in 7% of HBV positive patients (31). In Kermansha province, genotype D was found in 98.8% of HBV positive patients followed by genotype B in 1.2% of HBV positive patients (32). The distribution of HBV genotypes may guide us in determining the disease burden. HBV genotypes have been shown to differ with regard to prognosis, clinical outcomes and antiviral responses (33, 34). So, it is important to recognize the epidemiology of HBV genotyping as well and respond to this question: Is necessary, routine screening for hepatitis B in patients undergoing cardiac catheterization? The available data of the prevalence of HBV infection and the genotype of HBV in Iran are very heterogeneous. Therefore, this study was designed to determine and analyze the distribution of HBV infections in cardiac catheterization patients referred to the health centers in the north of Iran and identified the HBV genotypes applying polymerase chain reaction (PCR) during 2011-2013.

2. MATERIALS AND METHODS

In this cross-sectional study, during 2010-2013, serum samples were collected from 2560 patients who referred to Mazandaran heart center, Sari, Iran. Centrifuged and separated plasmas were immediately stored at -80°C. All samples had elevated serum aminotransferases a positive test for anti-HBsAg using enzyme linked immunosorbent assay (ELISA), and determined genotypes of HBV based using DNA extraction kit and appropriate protocol. A question was used to collect some information including the patients age, gender, employment status, and place of residence. These data were analyzed using descriptive statistics and SPSS V.19 and Chi-square test.

2.1. DNA extraction

DNA extraction from plasma samples was done using Mini EluteKit (Qiagen) and appropriate protocol. HBV was isolated from serum on following procedures; 200plasma of patients with 200 AL Buffer (Lyses Buffer) mixed for 15 seconds by vortex and incubated at 65°C for 15 minutes and then centrifuged quickly. Afterwards 250 Ethanol (96%-100%) was added and mixed for 15 seconds by vortex and incubated at room temperature, which was then added to QIAMP Mini Elute. Samples were centrifuged for one minute at 8000 revolutions per minute after finishing centrifuge, overlaid fluid separated and added in to the Sam volume. Next, tube content remained solution was washed with 500of AW1 Buffer and centrifuged for one minute at 8000 revolutions per minute and discharged overlaid fluid, and washed with 500 of AW2 Buffer and then washed with 500of Ethanol 96%-100%. Sample tubes were centrifuged again for one minute at 8000 revolutions per minute and incubate for 3 minutes at 65°C for drying. Finally, the pellet was re-suspended in 50 sterile distilled water and DNA quantification was determined using a spectrophotometer and resulted residue was solved for next stages. All samples were examined in the virology laboratory of Sari Medical School.

2.2. PCR Test

Plasma samples from HBsAg positive were confirmed for the presence of HBV nucleic acid and determined the genotypes of HBV genome. Total DNA was isolated from serum samples and PCR-Test was done using special Kit and according to special protocol with individual primers. All steps of preparing relational mix over ice resells have been performed and primers, after diluting, were stored in -20°C. Examination method summarized as follow: To make Master Mix 3%:1075 U distilled water, dNTP 30 ll, PCR Buffer IOX 150 ll and MgCl2 90 U. 11.5 U of above reaction was mixed with 0.2 U of Taq DNA polymerase, 40 pmol of each forward and reverse primers, 4ng of DNA sample and added dH20 that final reaction volume was 20 U. The samples were placed into the Eppendorf Master Cycler PCR machine and amplified. PCR program for amplification consisted of95°C for 5 minutes, followed by 35 cycles of94°C for 1 minute, 58.5°C for 1 minute and 72°C for 1 minute and finally, followed by 72°C for 10 minute.

2.3. Gel Electrophoresis

Agarose gel electrophoresis is an easy way to separate and visualize DNA fragments by their sizes. It is a common diagnostic procedure used in molecular biological labs. We use 1.5% Agarose gel loaded the DNA fragment from samples then they were separated by size. This is a graphic representation of an Agarose gel made by "running" DNA molecular weight markers. These gels were visualized on a UV analyzer by staining the DNA with a fluorescent dye (Ethidium bromide which is very carcinogenic). The DNA molecular weight marker is a set of DNA fragments of known molecular sizes that are used as a standard to determine the sizes of fragments.

3. RESULTS

During study period, we studied 2650 cardiac catheterization patients attending Mazandaran Heart Center in the North of Iran (Mazandaran province) from 2011 to 2013 were studied. The mean age of patients was 59.7±10.9 (range, 20 to 81) year that 1590 (60%) patients were male and 1060 (40%) was female. We found no patients with chronic hepatitis or had acute hepatitis. Among the pa-
The carrier variability rate for hepatitis B infection is estimated to be 0.1% to 20% throughout the world (5). In the Middle East, it has been reported that HBV infection is an intermediate rate, varying between 2% and 7% in different countries (35). In blood donors, this rate was 0.8% in Iran (36), 4% in Pakistan (37), 1.1–3.5% in Kuwait (38), 4.19% in Turkey (39) and 1.9% in Saudi Arabia (40). It was reported that the HBV infection indicates an intermediate rate in this country and the distribution of carrier rate of HBV infection in the different provinces of Iran was shown to be different (1.3% to 6.3%) (7). After HBV vaccination program, Iran can be considered as one of the countries with low HBV infection endemicity (8). Our results showed that the prevalence of HBV was 8 of cases in 1000 patients (%0.8), which highlights the value of HBV vaccination program. It can be concluded that, HBsAg rate among blood donors in Iran is still less in comparison with other neighboring countries of Iran.

At present, HBV has been classified into ten different genotypes (A–J) and multiple subtypes by genome sequencing of HBV strains (10–16). Genotypes of HBV have different geographic distribution in the world (41, 42). In this study, we found the genotype D of HBV in all HBsAg positive patients. Same to our study, it has been shown the HBV genotype D is distributed worldwide, and has been reported frequently (23–26, 43). Some studies from different part of Iran have reported that the genotype D is the only detectable genotype in the different clinical forms of HBV infection, including carriers HBV, chronic liver disease and cirrhosis (26–30) that is the same as our results. But, in the north of Iran, genotype D was found in 93% of HBV positive patients followed by genotype Bin 7% (31), and in another study, genotype D was found in 98.8% of HBV positive patients followed by genotype Bin 1.2% (32), that was different from our result because we found the genotype D of HBV in all samples of this study. It has been reported that the distribution of HBV genotypes was not just one genotype but some samples were mixed. It has been reported that 62.2% were found genotype D, 13% were found genotype A and 12%. Mixed genotype D+A was found in 12% of acute patients, 5.6% of chronic patients and 5.6% of carriers (43), 85.1% were genotyped as type D/E, 4.4% were genotyped as type A, 1.4% were genotyped as type C, and 0.7% were genotyped as type F (44) and other study was indicated the HBV genotype frequencies were: B, 57.9%; C, 16.0%; and BC, 26.1% (45). A study conducted among injecting drug users showed that the presence of genotype Din 62%, genotype A in 9% while 29% individuals were found to be infected with a mixture of genotype A and D (46). Genotypes A and D were most prevalent in co-infected patients with hepatitis C virus (HCV) in Iran. Same to our study, it has been shown the HBV genotype D is distributed worldwide, and has been reported among the 40–60 years old population. There was no significant relation between HBV genotypes and gender, disease and age group (Table 1).

| Table 1. Distribution of HBV according to gender, age group, employed and living place. |
|--------------------------------------------------|------------------|------------------|------------------|------------------|
| Gender                                           | HBV (+)          | HBV (-)          | Total            | Pvalue           |
| Female                                          | 10 (0.9)         | 1050 (99.1%)     | 1060 (100%)      | 0.664            |
| Male                                            | 12 (0.8)         | 1578 (99.2%)     | 1590 (100%)      | 0.718            |
| Age group                                       |                  |                  |                  |                  |
| <40                                             | 0 (0.0%)         | 40 (100%)        | 40 (100%)        |                  |
| 40-60                                           | 15 (0.9)         | 1613 (99.1%)     | 1628 (100%)      |                  |
| >60                                             | 7 (0.7)          | 975 (99.3%)      | 982 (100%)       |                  |
| Employed                                        |                  |                  |                  |                  |
| Self-employed                                   | 8 (0.8)          | 1087 (99.3%)     | 1095 (100%)      | 0.797            |
| Farmer                                          | 6 (1.1)          | 524 (98.9%)      | 530 (100%)       |                  |
| House keeper                                    | 8 (0.8)          | 982 (99.2%)      | 990 (100%)       |                  |
| Un-Employed                                     | 0 (0.0%)         | 35 (100%)        | 35 (100%)        |                  |
| Living place                                    |                  |                  |                  |                  |
| Urban                                           | 13 (0.6)         | 1917 (99.4%)     | 1930 (100%)      | 0.718            |
| Rural                                           | 9 (1.3)          | 711 (98.8%)      | 720 (100%)       |                  |

The electrophoresis pattern of HBV genotyping products were done by PCR using genotype specific primers. M is 100 bp marker, 1-4 are HBV positive samples, 5 and 6 are control positive samples.

4. DISCUSSION

The carrier variability rate for hepatitis B infection is estimated to be 0.1% to 20% throughout the world (5). In the Middle East, it has been reported that HBV infection is an intermediate rate, varying between 2% and 7% in different countries (35). In blood donors, this rate was 0.8% in Iran (36), 4% in Pakistan (37), 1.1–3.5% in Kuwait (38), 4.19% in Turkey (39) and 1.9% in Saudi Arabia (40). It was reported that the HBV infection indicates an intermediate rate in this country and the distribution of carrier rate of HBV infection in the different provinces of Iran was shown to be different (1.3% to 6.3%) (7). After HBV vaccination program, Iran can be considered as one of the...
Prevalence and Genotypes of Hepatitis B Virus Infection in Patients

HIV and HBV and so, HBV subtype A was present among three-fourth of patients infected through sexual contact, whereas the same percentage of subtype D was isolated among injection drug users (47).

HBV genotyping may guide us in selection of the duration and type of antiviral therapy and to predict the likelihood of sustained HBV clearance after therapy. It seems that there are different types of HBV genotypes in different parts of countries, due to wide range of geographical distribution and influence of the neighbors in the abundance of different types of HBV genotypes. Furthermore, factors such as repeated blood transfusion and treatment of the patients also can be some of the most important criteria which can cause this wide range of different genotypes. In conclusion, this research describes HBV genotyping in studied patients infected with HBV. This preliminary report describes that the genotype D is not the only genotype in the patients with HBsAg, which is different from other studies. Thus, further studies are needed to achieve the confirmation and so to determine the distribution of genotype of HBV subtype in patients with HBV positive.

Acknowledgments
This study was granted (grant number: 91-53) by Vice-Chancellor for Research of Mazandaran University of Medical Sciences. The authors highly thank all coworkers in Mazandaran heart center, Sari, Iran.

CONFLICT OF INTEREST: NONE DECLARED.

REFERENCES
1. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107.
2. Maynard JE. Hepatitis B: global importance and need for control. Vaccine. 1990; 8: 18-20.
3. Kane. Global program for control of hepatitis B infection. Vaccine. 1995; 13: 547-59.
4. Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP. Hepatitis B virus infection: epidemiology and vaccination.; Epidemiology Review. 2006: 28(1): 112-125.
5. Lee WM. Hepatitis B virus infection. N Engl J Med. 1997; 337(24):1733-1745.
6. Alavian SM. Hepatitis B virus infection in Iran; Changing the epidemiology. Iran J Clin Infect Dis. 2010; 5(1): 51-61.
7. Alavian SM, Hajarizadeh B, Ahmadzad-Asl M, KabirA, Baghери-Lankarani K. Hepatitis B virus infection in Iran: A Systematic Review. Hepatitis monthly. 2008; 8(4): 281-294.
8. Alavian SM. Ministry of Health in Iran Is Serious about Controlling Hepatitis B. Hepatitis Monthly. 2007; 7(1): 3-5.
9. Satish OS, Raghu C, Lakshmi V, Rao DS. Routine screening for HIV and hepatitis B in patients undergoing cardiac catheterisation: the need to make it mandatory. Indian Heart J. 1999; 51(3): 285-288.
10. Ganguly A, Rock MJ, Prockop DJ. Conformation-sensitve gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes . Proc Natl Acad Sci USA. 1993; 90(21): 10325-10329.
11. Norder H, Courouce AM, Magnus LO. Complete genomes, phylogenetic relatedness, and structural proteins of six strains of the hepatitis B virus, four of which represent two new genotypes. Virology. 1994; 198(2): 489-503.
12. Sakai T, Shiraki K, Inoue H, Okano H, Deguchi M, Sugimoto K, et al. HBV subtype as a marker of the clinical course of chronic HBV infection in Japanese patients. J Med Virol. 2002; 68(2): 175-181.
13. okamoto H, Tsuda F, Sakugawa H, Sastrosoewignjo RI, Imai M, Miyakawa Y, et al. Typing hepatitis B virus by homology in nucleotide sequence: comparison of surface antigen subtypes. J Gen Virol. 1988; 69(pt 10): 2575-2583.
14. Tong W, He J, Sun L, He S, Qi Q. Hepatitis B virus with a proposed genotype I was found in Sichuan Province, China. J Med Virol. 2012; 84(6): 866-870.
15. Huy TTT, Ngoc TT, Abe K. New .Complex Recombinant Genotype of Hepatitis B Virus Identified in Vietnam. Journal of Virology. 2008; 82(11): 5657-5663.
16. Tatematsu K, Tanaka Y, Kurbanov F, Sugauchi F, Mano S, Mae shiro T, et al. A Genetic Variant of Hepatitis B Virus Divergent from Known Human and Ape Genotypes Isolated from a Japanese Patient and Provisionally Assigned to New Genotype J J Gen Virol. 2009; 82(9): 10538-10547.
17. Alavian SM, Keyhani V, Rezai M, Ashayeri N, Sadeghi HM. Preliminary report of hepatitis B virus genotype prevalence in Iran. World J Gastroenterol. 2006; 12(32): 5211-5213.
18. Norder H, Courouce AM, Coursaget P, Echevarria JIM, Lee SD, Mushahwar IK, et al. Genetic diversity of hepatitis B virus strains derived worldwide: genotypes, subgenotypes, and HBsAg subtypes. Intervirology. 2009; 47(6): 289-309.
19. Baig S, Siddiqui AA, Chakravarty R, Moatter T, Unnissa T, Hasnain N, Phylogenetic analysis of hepatitis B virus in Pakistani patients with chronic HBV infection. J Med Virol. 2005; 76(4): 476-481.
20. Bozdagi Y, Tiirkylmaz AR, Idilman R, Karatayi E, Rota S, Yurdaydin C, et al. Complete genome sequence and phylogene tic analysis of hepatitis B virus isolated from Turkish patients infected with HBV. J Gen Virol. 2007; 88(pt 4): 835-839.
21. Bozdagi Y, AM, AN, Bozdagi Y, Tiirkylmaz AR, Seneger T, Wend U, et al. Molecular epidemiology of hepatitis B, C and D viruses in Turkish patients. Arch Virol. 2004; 149(11): 2115-2129.
22. Biswas A, Chandra PK, Datta S, Panigrahi R, Banerjee A, Chakrabarti S, et al. Frequency and distribution of hepatitis B virus genotypes among eastern Indian voluntary blood donors: Association with precore and basal core promoter mutations. Hepatol Res. 2009; 39(1): 53-59.
23. Attalla IH, Renan NU, Khan SU, Ali I, Ali S, Khan SN. Prevalence of Hepatitis B virus genotypes in HBsAg positive individuals of Afghanistan. Virol J. 2001; 7(8): 281.
24. Mohebbi SR, Amini-Bavil-Olyaee S, Zali N, Noorinayer B, De rakshan F, Chian M, et al. Molecular epidemiology of hepatitis B virus in Iran. Clin Microbiol Infect. 2008; 14(9): 858-866.
25. Bahramali G, Sadeghizadeh M, Amini-Bavil-Olyaee S, Alavian SM, Behzad-Bebahan A, Adeli A, et al. Clinical, virologic and phylogenetic features of hepatitis B infection in Iranian patients. World J Gastroenterol. 2008; 14(35): 5448-5453.
Prevalence and Genotypes of Hepatitis B Virus Infection in Patients

F, Abachi M, Azizi M, et al. Complete genomic sequence and phylogenetic relatedness of hepatitis B virus isolates from Iran. J Med Virol. 2005; 76(3): 318-326.

29. Mojiri A, Behzad-Behbahani A, Saberifrozi M, Ardabili M, Behesti M, Rahsaaz M, et al. Hepatitis B virus genotypes in southwest Iran: molecular, serological and clinical outcomes. World J Gastroenterol. 2008; 14(10): 1510-1513.

30. Vaezjalali M, Alavian SM, Jazayeri SM, Nategh R, Mahmoodi M, Hajibeigi B, et al. Genotype of Hepatitis B Virus Isolates from Iranian Chronic Carriers of the Virus. Hepatitis Monthly. 2008; 2(2): 97-100.

31. Haghshenas MR, Mousavi T, Rafei AR, Hosseini V, Hosseinikha Z. Prevalence of Hepatitis B virus genotypes with HBsAg positive patients in the Northern of Iran (Mazandaran) during 2010-2011. HealthMED. 2012; 6(5): 1568-1573.

32. Dokanehifard S, Bidmeshkipour A. A study of hepatitis B virus (HBV) genotypes in kermanshah province, west of Iran. Journal of biological sciences. 2009; 1(1): 113-120.

33. Yuen MF, Tanaka Y, Mizokami M, Yuen JC, Wong DK, Yuan HCJ, et al. Role of hepatitis B virus genotypes Ba and C, core promoter and precore mutations on hepatocellular carcinoma: a case control study. Carcinogenesis. 2004; 25(9): 1593-1598.

34. Thakur V, Sarin SK, Rehman S, Guptan RC, Kazim SN, Kumar S. Role of HBV genotype in predicting response to lamivudine therapy in patients with chronic hepatitis B. Indian J Gastroenterol. 2005; 24(1): 12-15.

35. Qirbi N, Hall AJ. Epidemiology of hepatitis B virus infection in the Middle East. East Mediterr. Health J. 2001; 7(6): 1034-1045.

36. Alavi-Moodian-Shooshlai M, Pourfathollah A. An overview analysis of blood donation in the Islamic Republic of Iran. Arch Iran Med. 2006; 9(3): 200-203.

37. Alam MM, Zaidi SZ, Malik SA, Naeem A, Shaukat S, Sharif S, et al. Serology based disease status of Pakistani population infected with Hepatitis B virus. BMC Infect Dis. 2007; 27(7): 64.

38. Ameen R, Sanad N, Al-Shemmar S, Siddique I, Chowdhury RI, Al-Hamdan S, et al. Prevalence of viral markers among first-time Arab blood donors in Kuwait. Transfusion. 2005; 45(12): 1973-1980.

39. Panhotra BR, Al-Bahrani A, Ul-Hassan Z. Epidemiology of antibody to hepatitis B core antigen screening among blood donors in Eastern Saudi Arabia. Need to replace the test by HBV DNA testing. Saudi Med J. 2005; 26(2): 270-273.

40. Khawaja RA, Khawaja AA. Hepatitis B virus Genotypes: Clinical & amp; Therapeutic Implications. J Pak Med Assoc. 2009; 59(2): 101-104.
Correlation Between Blood Lead Level and Hemoglobin Level in Mitrovica Children

Drita Kutllovci-Zogaj1,2, Selvete Krasniqi1,2, Isa Elezaj1,3, Naser Ramadani1,2, Tahire Gjergji1,2, Dukagjin Zogaj4, Arben Kutllovci4, Arbërësha Jaka2, Antigona Ukëhaxhaj2, Sanije Gashi1,2, Ergyl Bince2

Faculty of medicine, University of Prishtina, Prishtina, Kosova1
National Institute of Public Health of Kosova, Prishtina, Kosova2
Faculty of Biology, University of Prishtina, Prishtina, Kosova3
University Clinical Center of Kosova, Prishtina, Kosova4

Corresponding author: prof. Naser Ramadani, MD, PhD. National Institute of Public Health of Kosova, Mother Theresa Street NN., University Hospital Center, 10.000 Prishtina, Republic of Kosova, E-mail: naserramadani@gmail.com

ABSTRACT

Introduction: Lead toxicity is a serious health threat, especially in developing countries due to environmental pollution. It was thus aimed to investigate correlation between blood lead level and concentration level of hemoglobin in the blood of children involved in research.

Material and methods: The research included 250 children of which 31 (12.4%) kindergarten children, 166 (66.4%) of primary school pupils in Mitrovica and 53 (21.2%) of primary school pupils in Shëtime as control group. From the 250 children included in the survey 129 or 51.6% were female children and 48.4% male children. Children were selected randomly, while tests for concentration of Pb and blood hemoglobin were done at the National Institute of Public Health.

Results: The average value of blood lead level of Mitrovica pupils was 2.4 μg/dL (SD±1.9 μg/dL), range 0.5 to 16.3 μg/dL. The average value of blood lead level of Shëtime pupils was 2.3 μg/dL (SD±0.7 μg/dL), range 1.2 to 5.2 μg/dL with no statistical difference (P = 0.191). The average value of blood lead level in kindergarten children of Mitrovica was 3.8 μg/dL (SD±1.3 μg/dL), range 2.2 to 7.7 μg/dL with significant difference between the average values of blood lead levels of pupils and kindergarten children of Mitrovica (P <0.0001). The average value of hemoglobin in the pupils of Mitrovica was 14.0 g/dL (SD±3.7 g/dL), range 9.4 to 25.6 g/dL. The average value of hemoglobin to pupils of Shëtime was 11.4 g/dL (SD±0.8 g/dL), range 9.2 to 13.0 g/dL with significant difference between mean values of hemoglobin pupils of Mitrovica and Shëtime (U = 6440.0, P <0.0001). With Spearman correlation is found significant correlation of a medium scale (r = -0.305, df = 248, p <0.0001) between blood lead levels and hemoglobin level in the blood.

Key words: Blood lead level, Blood hemoglobin, Correlation.

1. INTRODUCTION

Lead exposure in children has received increasing attention from scientists and public health institutions worldwide.(1). There are many publications and information available concerning the effects of lead on human health. In fact, the toxic effects of lead have been known for centuries, but it has been discovered in recent decades, that the levels of exposure although to levels of lead in the blood (<20 μg/dL) are associated with negative effects in the body, are concerning (2, 3). In terms of public health, the issue of lead is an inevitable topic because the effects of lead are very harmful and toxic to our health. Lead has toxic effects in our brain, blood and kidneys. Children are the most vulnerable age group for exposure, because the exposure to high lead levels causes the impairment to their intellectual development.

Use of lead dating from ancient time. Lead is found naturally in the earth’s crust composition. However, most of the high levels found in the environment coming from human activities. Environmental levels of lead have risen more than 1000 times over the past three centuries as a result of industrial development where the use of lead is present (4).

At lower levels of exposure, which cause no obvious symptoms and that previously were considered safe, lead is now known to produce a spectrum of injury across multiple body systems. In particular, lead affects brain development in children, resulting in reduced IQ, behavioral changes such as shortening of attention span and increased antisocial behavior and reduced educational attainment. These effects are believed to be irreversible. Adults are at increased risk of kidney disease and raised blood pressure. CDC actually recognize <10 μg/dL even less as it possible (2).

Kosovo is landlocked and possesses many mineral resources, mainly coal, lead, zinc, chromium, and silver. Current industrial activity and a legacy of former practices have heavy health and environmental impacts and generate economic losses (5, 6, 7). These environmental issues relate to air pollution, lead and other contamina-